Editorial

Emerging Viral Resistance: Dealing with Uncertainty in Human Immunodeficiency Virus Chemoprophylaxis

Authors: Gabriel-Adrian Popescu, MD, PhD

Abstract

The therapeutic decision, a good example for choice theory, can become a hard task when many options exist in the absence of well-defined criteria to support it. The difficulties are greater in infectious diseases, where the treatment or chemoprophylaxis often needs to be initiated in the absence of resistance data concerning the antimicrobial susceptibility of etiological agent(s). This could result in suboptimal therapy increasing the risk of failure due to lack of activity against the etiological agent, or excessive therapy promoting an unnecessary risk of germ resistance.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.—2006. AIDS 2010;24:1203–212.
 
2. Bracciale L, Colafigi M, Zazzi M, et al. Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother 2009;64:607–615.
 
3. Youmans E, Tripathi A, Albrecht H, et al. Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005–2009. South Med J 2011;104:95–101.
 
4. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society—USA panel. Clin Infect Dis 2008;47:266–285.
 
5. Gatanaga H, Ibe S, Matsuda M, et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res 2007;75:75–82.
 
6. Yerly S, Junier T, Gayet-Ageron A, et al. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 2009;23:1415–1423.